

EMA/576582/2016 Corr

European Medicines Agency decision

P/0251/2016

of 23 September 2016

on the acceptance of a modification of an agreed paediatric investigation plan for nusinersen (EMA-001448-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0251/2016

of 23 September 2016

on the acceptance of a modification of an agreed paediatric investigation plan for nusinersen (EMA-001448-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0082/2014 issued on 31 March 2014,

Having regard to the application submitted by Biogen Idec Ltd on 30 May 2016 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan and proposing a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 19 August 2016, in accordance with Article 22 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision on the granting of a deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for nusinersen, solution for injection, intrathecal use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

A deferral for nusinersen, solution for injection, intrathecal use, the details of which are set out in the opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Biogen Idec Ltd, Innovation House, 70 Norden Road, SL6 4AY - Maidenhead, United Kingdom.

EMA/PDCO/397228/2016 Corr
London, 19 August 2016

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001448-PIP01-13-M02

Scope of the application

Active substance(s):

Nusinersen

Condition(s):

Treatment of spinal muscular atrophy

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Intrathecal use

Name / corporate name of the PIP applicant:

Biogen Idec Ltd

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Biogen Idec Ltd submitted to the European Medicines Agency on 30 May 2016 an application for modification of the agreed paediatric investigation plan as set out in the European Medicines Agency's decision P/0082/2014 issued on 31 March 2014.

The application for modification proposed changes to the agreed paediatric investigation plan and proposed a deferral.

The procedure started on 21 June 2016.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion;
 - to grant a deferral, the details of which are set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric Investigation Plan

2.1. Condition: treatment of spinal muscular atrophy

2.1.1. Indication(s) targeted by the PIP

- Treatment of infantile-onset spinal muscular atrophy;
- Treatment of later-onset spinal muscular atrophy.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	0	Not applicable.
Non-clinical studies	2	Study 1 Study to determine the local and systemic toxicity of nusinersen following intrathecal lumbar bolus injections to juvenile cynomolgus monkeys for 53 weeks and to assess the reversibility of any effects observed following a 26-week recovery period. (Study 396443-AS06) Study 2 Study to evaluate the pharmacokinetics of nusinersen following multiple dose intrathecal lumbar bolus injections to cynomolgus monkeys. (Study 396443-APK01)
Clinical studies	4	Study 3 Open-label, dose-range finding study to assess the safety and tolerability of multiple doses of nusinersen, in children with spinal muscular atrophy from 2 to less than 15 years of age. (Study ISIS 396443-CS2) Study 4 Open-label study to assess the efficacy, safety, tolerability and pharmacokinetics of multiple doses of nusinersen, in neonates and infants with spinal muscular atrophy from 21 days to less than or equal to 7 months (210 days) of age. (Study ISIS 396443-CS3A)

		Study 5 Double-blind, randomised, sham-procedure controlled study to assess the safety and efficacy of nusinersen as compared to sham-injection, in neonates and infants from birth to less than or equal to 7 months (210 days) of age at screening. (Study ISIS 396443-CS3B) Study 6 Double-blind, randomised, sham-procedure controlled study to assess the safety and efficacy of nusinersen as compared to sham-injection, in children with spinal muscular atrophy from 6 months to less than 18 years of age. (Study ISIS 396443-CS4)
--	--	--

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By August 2017
Deferral for one or more measures contained in the paediatric investigation plan:	Yes